NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
LSE · TRLS.L · GBp
Stock price, earnings
Quote as of Aug 25, 2026, 10:01 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Trellus Health plc’s quoted price sits in the lower half of its reported 52-week range, 94.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Trellus Health plc’s next earnings report is currently expected on May 11, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Trellus Health plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Trellus Health plc delivers digital health management services for long-term illnesses, primarily serving businesses and insurance companies. The cornerstone of their offerings is TrellusElevate, a secure, proprietary technology platform compliant with HIPAA regulations. This system enables the remote coordination and provision of individualized healthcare via telemedicine. Patients utilizing the platform gain access to dedicated care teams, comprehensive educational materials, and remote monitoring tools. This service specifically addresses inflammatory bowel diseases (IBD), encompassing chronic and incurable conditions like Crohn's Disease and ulcerative colitis. Founded in 2020, Trellus Health plc is headquartered in White Plains, New York.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
£0.24+£0.00 (+0.49%)
EKF Diagnostics Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 17.7% below the high.
£0.06-£0.00 (-1.73%)
Poolbeg Pharma PLC’s quoted price sits in the lower half of its reported 52-week range, 33.81% below the high.
£0.05-£0.00 (-1.39%)
Renalytix Plc’s quoted price sits in the upper half of its reported 52-week range, 36.01% below the high.
£0.00-£0.00 (-2.33%)
Verici Dx plc’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
£0.01+£0.00 (+3.45%)
Belluscura plc’s quoted price sits in the lower half of its reported 52-week range, 95.83% below the high.
